Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial

被引：0

作者：

Dargent, Auguste ^{[1
,2
]}

Bourredjem, Abderrahmane ^{[3
]}

Jacquier, Marine ^{[4
]}

Bohe, Julien ^{[1
]}

Argaud, Laurent ^{[5
]}

Levy, Bruno ^{[6
,7
]}

Fournel, Isabelle ^{[3
]}

Cransac, Amelie ^{[8
]}

Badie, Julio ^{[9
]}

Quintin, Luc ^{[10
]}

Quenot, Jean-Pierre ^{[4
,11
]}

机构：

[1] Hosp Civils Lyon, Lyon Sud Hosp, Anesthesia & Crit Care Dept, Lyon, France

[2] APCSe Lab, VetAgro Sup UPSP 2016 A101, Marcy Letoile, France

[3] Univ Bourgogne, INSERM, CHU Dijon Bourgogne, Module Epidemiol Clin,CIC 1432, Dijon, France

[4] CHU Dijon, Med Intens Care Dept, Dijon, France

[5] Hosp Civils Lyon, Edouard Herriot Hosp, Med Intens Care Dept, Lyon, France

[6] CHU Nancy Brabois, Med Intens Care Dept, Nancy, France

[7] INSERM, U1116, Inst Coeur & Vaisseaux, Grp Choc,Equipe 2,Fac Med, Nancy, France

[8] CHU Dijon, Dept Pharm, Dijon, France

[9] Hop Nord Franche Comte, Crit Care Dept, Trevenans, France

[10] Desgenettes Mil Hosp, Lyon, France

[11] Bourgogne Franche Comte Univ, INSERM UMR1231, LabEx LipSTIC Res Unit, Lipness Team, Dijon, France

来源：

CRITICAL CARE MEDICINE | 2025年 / 53卷 / 04期

关键词：

alpha-2; agonists; dexmedetomidine; refractory septic shock; septic shock; vasopressors; ENDOTOXIN-INDUCED SHOCK; INFLAMMATORY RESPONSES; SEPSIS; NOREPINEPHRINE; MORTALITY; PHENYLEPHRINE; CLONIDINE; SEDATION; PROPOFOL;

D O I：

10.1097/CCM.0000000000006608

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

OBJECTIVES:Increasing evidence has suggested the benefits of dexmedetomidine in patients with sepsis. Dexmedetomidine may increase vasopressor sensitivity, which may be of interest in the setting of refractory septic shock. The alpha 2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS) pilot study aimed to evaluate the effect of dexmedetomidine on the vasopressor response in patients with refractory septic shock. DESIGN:This study was a multicenter, randomized, placebo-controlled, double-blind pilot trial. SETTING:The study was conducted in 5 ICUs in France. PATIENTS:Inclusion criteria were septic shock (Sepsis-3 definition) and norepinephrine requirement greater than or equal to 0.25 mu g/kg/min (0.5 mu g/kg/min of norepinephrine tartrate) with persistent circulatory failure (defined by lactate > 2 mmol/L, oliguria, or skin mottling) and invasive mechanical ventilation. INTERVENTIONS:The arterial pressure response to phenylephrine was measured before starting the treatment (0 hr), at 6 hours (primary outcome), and 12 hours. In the treatment arm, dexmedetomidine was given at a fixed dose of 1 mu g/kg/hr. MEASUREMENTS AND MAIN RESULTS:Inclusions were stopped early because of higher mortality in the dexmedetomidine arm. Thirty-two patients of the 36 planned were included. Response to phenylephrine at 6 hours was lower in the dexmedetomidine group than in the placebo group (1.26 +/- 0.23 vs. 1.45 +/- 0.26; p = 0.048), although this difference was also observed at baseline (p = 0.029). There were no significant differences between the groups in terms of cumulative norepinephrine dose, lactatemia, Sequential Organ Failure Assessment score, fluid balance, ventilation-free days, or occurrence of bradycardia. Mortality on day 3 was higher in the dexmedetomidine group than in the placebo group, with a difference that diminished and was no longer significant on 30 and 90 days. CONCLUSIONS:Patients in the dexmedetomidine arm had a significantly lower response to phenylephrine at all study times including baseline, which might have contributed to higher early mortality in the dexmedetomidine arm and preclude to conclude on dexmedetomidine efficacy in refractory septic shock. However, heart rate was not decreased in the dexmedetomidine arm.

引用

页码：e884 / e896

页数：13

共 38 条

[1] Daviaud F., Grimaldi D., Dechartres A., Et al., Timing and causes of death in septic shock, Ann Intensive Care, 5, (2015)
[2] Quenot J.-P., Binquet C., Kara F., Et al., The epidemiology of septic shock in French intensive care units: The prospective multicenter cohort EPISS study, Crit Care, 17, (2013)
[3] Auchet T., Auchet T., Regnier M.-A., Et al., Outcome of patients with septic shock and high-dose vasopressor therapy, Ann Intensive Care, 7, (2017)
[4] Dargent A., Nguyen M., Fournel I., Et al., Vasopressor cumulative dose requirement and risk of early death during septic shock: An analysis from the EPISS cohort, Shock, 49, pp. 625-630, (2017)
[5] Avontuur J.A., Nolthenius R.P.T., Buijk S.L., Et al., Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock, Chest, 113, pp. 1640-1646, (1998)
[6] Svoboda P., Scheer P., Kantorova I., Et al., Terlipressin in the treatment of late phase catecholamine-resistant septic shock, Hepatogastroenterology, 59, pp. 1043-1047, (2012)
[7] Varpula M., Tallgren M., Saukkonen K., Et al., Hemodynamic variables related to outcome in septic shock, Intensive Care Med, 31, pp. 1066-1071, (2005)
[8] Lambden S., Creagh-Brown B.C., Hunt J., Et al., Definitions and pathophysiology of vasoplegic shock, Crit Care, 22, (2018)
[9] Bellissant E., Annane D., Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock, Clin Pharmacol Ther, 68, pp. 293-303, (2000)
[10] Conrad M., Perez P., Thivilier C., Et al., Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure, J Crit Care, 30, pp. 739-743, (2015)

← 1 2 3 4 →